drugset / Trial / NCT05092802
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
NaSingle-groupOpen-labelTreatment
Summary
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
Timeline
- Start
- 2021-12-23
- Primary completion
- 2023-05-30
- Completion
- 2024-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX208 | Unknown | 450 mg | Oral |